Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. - AlzForum Alzheimer Research Paper of the Week


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		AlzSWAN
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: Papers of the Week

Annotation

	Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001 Jan 15;20(1-2):27-39. PubMed Abstract, View on AlzSWAN Corresponding Author: Jesus Avila

	Comments on Paper and Primary News

	Comment by: Benjamin Wolozin, ARF Advisor (Disclosure)
	Permalink
	I recommend this paper "This paper provides in vivo support for a putative role of GSK in the regulation of catenin and tau phosphorylation." View all comments by Benjamin Wolozin

	Comment by: Eddie Koo, ARF Advisor
	Permalink
	I recommend this paper "Good in vivo experimental evidence of GSK phosphorylating tau. Previously, most brain evidence has been correlative." View all comments by Eddie Koo

	Comments on Related Papers

	Related Paper: Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Comment by: Hiroshi Mori, ARF Advisor
	Permalink
	GSK-3 is proposed to be located at the upstream of pathology from the binding of presenilin-1. The total cascade will go to more complex but interesting issue. View all comments by Hiroshi Mori

	Related Paper: Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Comment by: Paul Coleman, ARF Advisor
	Permalink
	This ability of PS 1 to link GSK-3-beta with tau may be particularly important in view of the role that GSK-3-beta appears to play in phosphorylating tau. View all comments by Paul Coleman

Submit a Comment on this Paper

Cast your vote and/or make a comment on this paper.

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name
*Last Name
Country or Territory:
*Login Email Address
*Password	Minimum of 8 characters
*Confirm Password
Stay signed in?

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:

*Enter the verification code you see in the picture below:

This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:	Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.

REAGENTS/MATERIAL:
8.0 kb AseI BitetO fragment was microinjected into single-cell CBAxC57BL/6 embryos for the generation of transgenic mice 7.51 antibody (Dr. Wischik) PHF-1 antibody (Dr. Davies), react with tau when serines 396 and 404 are phosphorylated 12E8 antibody (Dr. Seubert), react with tau when serine 262 is phosphorylated AD2 antibody (Dr. Mourton-Giles), react with tau when serines 396 and 404 are phosphorylated OX42 antibody (Dr. Bovolenta) USsnRNP antibody (Dr. Ortin) GSK3beta and Beta-catenin antibodies (Transduction Laboratories) Beta-tubulin antibody (Sigma) GFAP antibody (PharMingen) ED1 antibody (Serotec) Cleaved caspase-3 antibody (Cell Signaling Technology)

FUTURE DIRECTION:
More study on beta-catenin is needed, such as the target genes that are transactivated by beta-catenin that are responsible for the increased susceptibility of apoptosis. Further elucidation on the contribution of GSK-3beta to neurodegeneration.

Print this page

Email this page

Alzforum News

Papers of the Week

Text size

Share & Bookmark

Antibodies

Cell Lines

Collaborators

Papers

Research Participants